Which place for a dual or triple inhibition of the renin-angiotensin- aldosterone system?;Quelle place pour une double ou triple inhibition du système rénine-angiotensine-aldostérone?

Revue Medicale Suisse

Volumn 4, Issue 168, 2008, Pages 1792-1797

  Legrand, Delphine ^a   Krzesinski, Jean Marie ^a   Scheen, André J ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE RECEPTOR; ALISKIREN; ANGIOTENSIN 1 RECEPTOR; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; RAMIPRIL; TELMISARTAN; VALSARTAN;

CARDIOVASCULAR DISEASE; CONGESTIVE HEART FAILURE; DIABETIC NEPHROPATHY; DRUG EFFECT; DRUG MECHANISM; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; MORBIDITY; MORTALITY; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK BENEFIT ANALYSIS;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOVASCULAR DISEASES; HUMANS; KIDNEY DISEASES; RENIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 51549108945     PISSN: 16609379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. Stojiljkovic L, Behnia R. Role of renin angiotensin system inhibitors in cardiovascular and renal protection : A lesson from clinical trials. Curr Pharm Des 2007;13:1335-45.
2. Cohn JN. Reducing cardiovascular risk by blockade of the renin-angiotensin-aldosterone system. Adv Ther 2007;24:1290-304.
3. White WB. Angiotensin-converting enzyme inhibitors in the treatment of hypertension : An update. J Clin Hypertens 2007;9:876-82.
4. Jorde UP. Suppression of the renin-angiotensin-aldosterone system in chronic heart failure : Choice of agents and clinical impact. Cardiol Rev 2006;14:81-7.
5. * Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BM. Renin-angiotensin system and cardiovascular risk. Lancet 2007;369:1208-19.
6. Gurley SB, Coffman TM. The renin-angiotensin system and diabetic nephropathy. Semin Nephrol 2007;27:144-52.
7. * Balamuthusamy S, Srinivasan L, Verma M, et al. Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinura : A meta-analysis. Am Heart J 2008;155:791-805.
8. Scheen AJ. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part I. A meta-analysis of randomised clinical trials. Diabetes Metab 2004;30:487-96.
9. Thomas GN, Tomlinson B. Prevention of macrovascular disease in type 2 diabetic patients : Blockade of the renin-angiotensin-aldosterone system. Curr Diabetes Rev 2008;4:63-78.
10. * Weir MR. Effects of renin-angiotensin system inhibition on end-organ protection : Can we do better? Clin Ther 2007;29:1803-24.
11. Werner C, Baumhäkel M, Teo KK, et al. RAS blockade with ARB and ACE inhibitors : Current perspective on rationale and patient selection. Clin Res Cardiol 2008;97:418-31.
12. Schleich F, Krzesinski JM, Piérard L, Scheen AJ. Comment je traite. . . en optimisant le blocage du système rénine- angiotensine-aldostérone. Rev Med Liège 2008;63:174-81.
13. Blumenfeld JD, Sealey JE, Mann SJ, et al. Beta-adrenergic receptor blockade as a therapeutic approach for suppressing the renin-angiotensin- aldosterone system in normotensive and hypertensive subjects. Am J Hypertens 1999;12:451-9.
14. Struthers AD. Aldosterone blockade in cardiovascular disease. Heart 2004;90:1229-34.
15. * Sato A, Saruta T, Funder JW. Combination therapy with aldosterone blockade and renin-angiotensin inhibitors confers organ protection. Hypertens Res 2006;29:211-6.
16. Dendorfer A, Dominiak P, Schunkert H. ACE inhibitors and angiotensin II receptor antagonists. Handb Exp Pharmacol 2005;170:407-42.
17. Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet 2000;355:637-45.
18. Gradman AH, Kad R. Renin inhibition in hypertension. J Am Coll Cardiol 2008;51:519-28.
19. Shafiq MM, Menon DV, Victor RG. Oral direct renin inhibition : Premise, promise, and potential limitations of a new antihypertensive drug. Am J Med 2008;121:265-71.
20. Doulton TW, He FJ, MacGregor GA. Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension. Hypertension 2005;45:880-6.
21. Weber MA. New opportunities in cardiovascular patient management : A survey of clinical data on the combination of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Am J Cardiol 2007;100(3A):45J-52.
22. * Azizi M, Wuerzner G. Rationale for combining blockers of the renin-angiotensin system. Semin Nephrol 2007;27:544-54.
23. Cohn JN, Goldman JM. Establishing a new option for target-organ protection : Rationale for ARB plus ACE inhibitor combination therapy. Am J Hypertens 2008;21:248-56.
24. Bakris GL, Weir MR. Comparison of dual RAAS blockade and higher-dose RAAS inhibition on nephropathy progression. Postgrad Med 2008;120:33-42.
25. * The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-59.
26. Carey RM, Siragy HM. Newly recognized components of the renin-angiotensin system : Potential roles in cardiovascular and renal regulation. Endocr Rev 2003;24:261-71.
27. Atlas SA. The renin-angiotensin aldosterone system : Pathophysiological role and pharmacologic inhibition. J Manag Care Pharm 2007;13(Suppl. S-b):S9-20.
28. Bakris GL, Ruilope L, Locatelli F, et al. Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk : Results of the IMPROVE trial. Kidney Int 2007;72:879-85.
29. Nakao N, Yoshimura A, Morita H, et al. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting- enzyme inihibitor in non-diabetic renal disease (COOPERATE) : A randomised controlled trial. Lancet 2003;361:117-24.
30. * McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors : The CHARM-Added trial. Lancet 2003;362:767-71.
31. Cohn JN, Tognoni G; Valsartan Heart failure trial investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-75.
32. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893-906.
33. Waeber B. Le renouveau des antagonistes de l'aldostérone. Rev Med Suisse 2006;2:2055-8.
34. Pitt B, Zannad F, Remme WJ, et al for the Randomized aldactone evaluation study investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-17.
35. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-21.
36. McManus F, McInnes GT, Connell JMC. Drug insight : Eplerenone, a mineralocorticoid-receptor antagonist. Nat Clin Pract Endocrinol Metab 2008;4:44-52.
37. Shah NC, Pringle S, Struthers A. Aldosterone blockade over and above ACE-inhibitors in patients with coronary artery disease but without heart failure. J Renin Angiotensin Aldosterone Syst 2006;7:20-30.
38. * Staessen JA, Li Y, Richart T. Oral renin inhibitors. Lancet 2006;368:1449-56.
39. Frampton JE, Curran MP. Aliskiren. A review of its use in the management of hypertension. Drugs 2007;67:1767-92.
40. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK, for the AVOID study investigators. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008;358:2433-46.
41. Chrysant SG, Murray AV, Hoppe UC, et al. Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension : A 6-month interim analysis. Curr Med Res Opin 2008;24:1039-47.
42. Cravedi P, Ruggenenti P Remuzi G. Intensified inhibition of renin-angiotensin system : A way to improve renal protection ? Curr Hypertens Rep 2007;9:430-6.
43. Jneid H, Moukarbel GV, Dawson B, Hajjar RJ, Francis GS. Combining neuroendocrine inhibitors in heart failure : Reflections on safety and efficacy. Am J Med 2007;120:1090.e1-8.
44. Tylicki L, Rutkowski P, Renke M, et al. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabettc CKD : An open-label crossover randomized controlled trial. Am J Kidney Dis 2008 Apr 17. Epub ahead of print.
45. Furumatsu Y, Nagasawa Y, Tomida K, et al. Effect of renin-angiotensin- aldosterone system triple blockade on non-diabetic renal disease : Addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker. Hypertens Res 2008;31:59-67.
46. Weir RA, McMurray JJ, Puu M, et al. Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the candesartan in heart failure : Assessment of reduction in mortality and morbidity (CHARM)-Added trial. Eur J Heart Fail 2008;10:157-63.